Stockreport

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada; Potential for revenue in Canada alone of $100-150 million dollar [Read more]